**Memorandum of Understanding:**

**Pharmacogenomics Research Network (PGRN): Clinical Pharmacogenomics Implementation Consortium (CPIC)**

***Summaries and Publications***

**Date: February 21, 2010 Updated November 1, 2010**

**Background**

One of the major activities of the CPIC will be to create clinically-relevant summaries on using pharmacogenomics in clinical practice.

In particular, there is an opportunity to put these summaries and recommendations into publishable white papers, and to store them on PharmGKB with extensive links and perhaps expanded documents with supporting data. PharmGKB scientists are trained in summarizing the literature, and linking to relevant evidence base, and PharmGKB has an interest in disseminating the results of pharmacogenomic research that has clinical implications on its website.

**Proposal**

1. For gene/drug guidelines, each prioritized gene will provide the main organizing principle around which a writing committee will form. Decisions as to how to handle drug-specific recommendations for each gene will be made by the writing committee, with input from the CPIC.
2. Publication authors acknowledge that they will be familiar with and support CPIC activities, and that they have read the MOU describing requirements for CPIC members.
3. Authors of CPIC publications agree to announce their intention to create and lead a document about clinical implementation of pharmacogenomics to the entire CPIC, and allow other members to participate as collaborators, assuming they fulfill the expectations in item (3) above. In general, there will be a PharmGKB representative to assist in literature review and to prepare primary and supporting documents for posting on PharmGKB. The PharmGKB representative will also establish and maintain appropriate “Google Group” (or other appropriate) web sites for email and document exchange.
4. Members working on particular documents will generally be the primary authors of CPIC reports, with authorship requiring substantial participation in the evaluation and summarization of evidence and in creation of the document. The leader of each effort will convene a discussion of authorship at appropriate phases of the project (early, middle, late) to ensure that there are clear expectations.
5. Publication in peer-reviewed journals will be coordinated by CPIC with PGRN and PharmGKB input. Authors will agree to sign relevant copyright agreements for the peer-reviewed journals. Published summaries should strive to have a standardized organization and appearance.
6. All documents will be available after publication on PharmGKB directly (and linked to the journal), and will be associated with supporting documents created by the authors in support of their clinical recommendation summaries.
7. CPIC recommendations should be based primarily on published data. If the authors believe that unpublished data are critical for a recommendation, the data should be made available on PharmGKB for transparency.
8. When a paper is published based on all or some of the aggregated data set, the supporting information, if any, on which the paper is based will be transferred to the PharmGKB "public" site, simultaneously with publication.
9. With publication and release of the data on the public site, PharmGKB and the CPIC will engage in appropriate dissemination, announcements, and emphasis of the availability of this exciting information to the community.
10. CPIC guidelines, including the formatted template, are to be handled like confidential materials and are embargoed prior to publication like other manuscripts.
11. Guideline authors agree to abide by "Authorship on CPIC Guidelines,” including declaring possible conflicts of interest for review by the CPIC Steering Committee.

Name \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Affiliation \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Signature line \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Date \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_